KINDERÄRZTE.SCHWEIZ 4/2020

27 04 / 2020 FORTB I LDUNG: THEMENHEFTTE I L K I N D E R Ä R Z T E . SCHWEIZ 45. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory medicine. 2020;8(4):e21. 46. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay be- tween inflammation and coagulation. The Lancet Respiratory Med- icine. 47. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel corona- virus pneumonia. J Thromb Haemost. 2020;18(4):844–847. 48. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of COVID-19 in the Young. N Engl J Med. 2020;382(20):e60. 49. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. 50. Basatneh R, Vlahovic TC. Addressing the Question of Dermatolog- ic Manifestations of SARS-CoV-2 Infection in the Lower Extremi- ties: A Closer Look at the Available Data and its Implications. J Am Podiatr Med Assoc. 2020. 51. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Ital- ian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771–1778. 52. Viner RM, Whittaker E. Kawasaki-like disease: emerg- ing complication during the COVID-19 pandemic. Lancet. 2020;395(10239):1741–1743. 53. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Segal JB, et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp Pediatr. 2020;10(6):537–540. 54. Moreira A. Kawasaki disease linked to COVID-19 in children. Na- ture reviews Immunology. 2020;20(7):407. 55. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflammatory syndrome in chil- dren during the COVID-19 pandemic in Paris, France: prospective observational study. BMJ (Clinical research ed). 2020;369:m2094. 56. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, The- ocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608. 57. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nature Reviews Immunology. 2020;20(8):457– 458. 58. Dijkman R, Jebbink MF, El Idrissi NB, Pyrc K, Muller MA, Kuijpers TW, et al. Human coronavirus NL63 and 229E seroconversion in children. Journal of clinical microbiology. 2008;46(7):2368–2373. 59. Kaye HS, Marsh HB, Dowdle WR. Seroepidemiologic survey of coronavirus (strain OC 43) related infections in a children’s popu- lation. Am J Epidemiol. 1971;94(1):43–49. 60. Isaacs D, Flowers D, Clarke JR, Valman HB, MacNaughton MR. Epidemiology of coronavirus respiratory infections. Arch Dis Child. 1983;58(7):500–503. 61. Monto AS, Lim SK. The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection. The Journal of infectious diseases. 1974;129(3):271– 276. 62. Lv H, Wu NC, Tsang OT, Yuan M, Perera R, Leung WS, et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020;31(9):107725. 63. Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding an- tibodies are more sensitive than neutralizing antibodies in identi- fying coronavirus-associated illnesses. Journal of medical virology. 2020;92(5):512–517. 64. Nye S, Whitley RJ, Kong M. Viral Infection in the Development and Progression of Pediatric Acute Respiratory Distress Syndrome. Fron- tiers in pediatrics. 2016;4:128. 65. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) vi- rus infection. N Engl J Med. 2010;362(18):1708–1719. 66. Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022. 67. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and Other Clinical Characteristics of COVID-19 in Children. Pediatrics. 2020;146(1). 68. Gonzalez AJ, Ijezie EC, Balemba OB, Miura TA. Attenuation of In- fluenza A Virus Disease Severity by Viral Coinfection in a Mouse Model. Journal of virology. 2018;92(23). 69. Nickbakhsh S, Mair C, Matthews L, Reeve R, Johnson PCD, Thor- burn F, et al. Virus-virus interactions impact the population dy- namics of influenza and the common cold. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(52):27142–27150. 70. Mannheim J, Gretsch S, Layden JE, Fricchione MJ. Characteris- tics of Hospitalized Pediatric COVID-19 Cases – Chicago, Illinois, March–April 2020. J Pediatric Infect Dis Soc. 2020. 71. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA pediatrics. 2020. 72. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children’s Hospi- tal in New York City, New York. JAMA pediatrics. 2020:e202430– e202430. 73. Moorlag S, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clinical microbiology and infec- tion: the official publication of the European Society of Clinical Mi- crobiology and Infectious Diseases. 2019;25(12):1473–1478. 74. Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, Antonakos N, Kot- saki A, Domínguez-Andrés J, et al. Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell. 2020. 75. Franklin R, Young A, Neumann B, Fernandez R, Joannides A, Reya- hi A, et al. Homologous protein domains in SARS-CoV-2 and mea- sles, mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVID-19. medRxiv; 2020. 76. Initiative PGE. The use of oral polio vaccine (OPV) to prevent SARS- CoV2. Published 2020. Accessed 6th June 2020. 77. Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. The Lancet. 2020;395(10236):1545–1546. 78. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf). 2005;62(3):265–281. 79. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. The American journal of clin- ical nutrition. 2000;72(3):690–693. 80. Restrepo Valencia CA, Aguirre Arango JV. Vitamin D (25(OH)D) in patients with chronic kidney disease stages 2-5. Colomb Med (Cali). 2016;47(3):160-166. 81. D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchi- ni R, et al. 25-Hydroxyvitamin D Concentrations Are Lower in Pa- tients with Positive PCR for SARS-CoV-2. Nutrients. 2020;12(5). 82. De Smet D, De Smet K, Herroelen P, Gryspeerdt S, Martens GA. Vita- min D deficiency as risk factor for severe COVID-19: a convergence of two pandemics. medRxiv. 2020:2020.2005.2001.20079376. 83. CDC CfDCaP. Vitamin D, https://www.cdc.gov/breastfeeding/ breastfeeding-special-circumstances/diet-and-micronutrients/ vitamin-d.html. Published 14 December 2019. Accessed 16 June 2020. 84. Iguichi H, Kato KI, Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endo- crinol Metab. 1982;55(1):27–29. 85. Waldhauser F, Weiszenbacher G, Tatzer E, Gisinger B, Waldhauser M, Schemper M, et al. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab. 1988;66(3):648–652. 86. Haldar C, Yadav R, Alipreeta. Annual reproductive synchronization in ovary and pineal gland function of female short-nosed fruit bat, Cynopterus sphinx. Comp Biochem Physiol A Mol Integr Physiol. 2006;144(4):395–400. 87. Feitosa EL, Júnior F, Nery Neto JAO, Matos LFL, Moura MHS, Ro- sales TO, et al. COVID-19: Rational discovery of the therapeutic po- tential of Melatonin as a SARS-CoV-2 main Protease Inhibitor. In- ternational journal of medical sciences. 2020;17(14):2133–2146.